MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
Open Access
- 29 August 2017
- journal article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (8), e0183458
- https://doi.org/10.1371/journal.pone.0183458
Abstract
Correct risk assessment of disease recurrence in patients with early breast cancer is critically important to detect patients who may be spared adjuvant chemotherapy. In clinical practice this is increasingly done based on the results of gene expression assays. In the present study we compared the concordance of the 70-gene signature MammaPrint (MP) with the 12 gene assay EndoPredict (EP). Representative tissue of 48 primary tumours was analysed with the MP during routine diagnostic purposes. Corresponding formalin-fixed, paraffin-embedded tissue was thereafter analysed by the EP test. Risk categories of both tests were compared. 41 of 48 tumours could be directly compared by both tests. Of the 17 MP low risk cases, only 9 were considered low risk by EP (53% agreement) and of the 24 MP high risk cases, 18 were high risk by EP (75% agreement). Discrepancies occurred in 14 of 41 cases (34.1%). There was only a weak and non-significant correlation between the MP and EP test with an overall concordance of only 66%. The original therapeutic recommendation was based on the MP and would have been changed in 38% of the patients following EP test results. 4 patients developed distant metastases. The respective tumours of these patients were all classified as high risk by the EP, but only 3 were classified as high risk by the MP. Both tests resulted in different treatment recommendations for a significant proportion of patients and cannot be used interchangeably. The results underscore the urgent need for further comparative analyses of multi-genomic tests to avoid misclassification of disease recurrence risk in breast cancer patients.This publication has 44 references indexed in Scilit:
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyInternational Journal of Cancer, 2013
- EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerAnnals of Oncology, 2012
- Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assayVirchows Archiv A Pathological Anatomy and Histopathology, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal CohortClinical Cancer Research, 2008
- Molecular profiling in breast cancerReviews in Endocrine and Metabolic Disorders, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- The Hallmarks of CancerCell, 2000